Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12509148 | 0.95 | FAAH (0.62) | FAAHF10NPC1MAOBKDM1A | |
| SCHEMBL12509344 | 0.91 | FAAH (0.58) | FAAHF10NPC1MAOBKDM1A | |
| SCHEMBL12509226 | 0.91 | FAAH (0.58) | FAAHF10NPC1MAOBKDM1A | |
| SCHEMBL2194385 | 0.90 | PPARA (0.59) | FAAHNPC1 | |
| SCHEMBL12509231 | 0.90 | FAAH (0.57) | FAAHF10NPC1MAOBF2 | |
| SCHEMBL2195419 | 0.89 | FAAH (0.56) | FAAHMAOBMAOA | |
| SCHEMBL12508773 | 0.89 | FAAH (0.59) | FAAHF10NPC1MAOBKDM1A | |
| SCHEMBL2193950 | 0.88 | FAAH (0.56) | FAAHF10MAOBKDM1ARCOR1 | |
| SCHEMBL12509347 | 0.88 | FAAH (0.66) | FAAHF10MAOBKDM1AF2 | |
| SCHEMBL12508511 | 0.88 | FAAH (0.61) | FAAHF10MAOBKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | FAAH 1/4885MET 4650/4885F10 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.